Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2016

View Archived Issues

GnHR antagonist SKI-2670 well tolerated, suppresses hormones in phase I trial

Sirenas enters drug discovery collaboration with Calibr

U.K. Dstl gets funding to study inhaled ciprofloxacin in biodefense

Two mutations at the same anticodon stem pair may cause different myopathic phenotypes

Hookipa Biotech presents data on CMV vaccine candidate

PSMA ligand [99mTc]MIP-1427 improves diagnostics in osseous metastasized prostate cancer

Argonaut Therapeutics raises funds to develop cancer drugs

Advanced Proteome Therapeutics acquires option to antibody candidates from University of Toronto

Pfizer wins grant from Bill & Melinda Gates Foundation for GBS vaccine trial

Omeros reports results from phase II study of PPARgamma agonist in cocaine use disorder

Merck & Co. patents TrK-A inhibitors

Shionogi discloses ACC2 inhibitors

FDA grants accelerated approval for Lartruvo in soft tissue sarcoma

Takeda Pharmaceutical describes ACC1 inhibitors

Fujifilm Kyowa Kirin Biologics reports phase III results for adalimumab biosimilar FKB-327

Spotlight Innovation obtains exclusive worldwide license for STL-182

ICGEB and Sun Pharma collaborate on new tetravalent dengue vaccine

Pivotal phase III study of letermovir meets primary endpoint

Texas A&M University develops pateamine A analogues

Incyte presents LSD1 inhibitors

MHRA accepts XOMA's proposal for phase II study of XOMA-358 in congenital hyperinsulinism

Cerulean collaborates with Novartis to develop nanoparticle-drug conjugate product candidates

Rare SHANK3 mutation may be a risk factor for ASD and schizophrenia

Applied Genetic Technologies files IND for second achromatopsia therapeutic candidate

Australian NHMRC funds research in chronic lung diseases

Perlara forms drug discovery collaboration with Novartis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...